WinstonWınston
Carasent AB logo

Carasent AB

CARA.ST
47
Software - Application · Technology
Price
kr 24.20
-0.25 (-1.02%)
Market Cap
kr 1.62B
Exchange
Stockholm Stock Exchange
Winston Score
47
Winston is serious
Mixed quality — meaningful strengths and weaknesses.

Share count rising — dilution

+3.3% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 67.1M (2021) → 69.3M (2025)

Carasent is a Swedish software company that builds digital tools for doctors and healthcare clinics. Its main product is Webdoc, an electronic health record (EHR) system used by private healthcare providers across Scandinavia. The company helps clinics manage patient records, appointments, and clinical workflows in one place.

Carasent makes money by charging healthcare providers recurring subscription fees for its software, which gives it a relatively predictable revenue stream. It operates primarily in Sweden, Norway, and the broader Nordic region, and its high gross margin of roughly 84% reflects the low cost of delivering software at scale. The company's main competitive advantage is the switching cost built into EHR systems — once a clinic's data and workflows are embedded in a platform, changing to a competitor is slow and disruptive. The key risk is that operating margins remain very thin, meaning the company must grow revenue significantly to prove its business model can generate meaningful profits.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+6.1% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+200.0% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$0/ year

0.0% of revenue

Below sector average (15%)

Research and development spending

Insider Activity

4.7%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$130M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Carasent AB is growing revenue at 6% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
84.6%
Premium pricing power — 84.6% gross margin
Operating Margin
1.8%
Thin — 1.8% operating margin
ROCE
0.2%
Weak — 0.2% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+26.5%
Fast-growing sales (26.5% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
344%
Turns 344% of profit into real cash
FCF Margin
11.8%
Modest free cash flow (11.8%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
N/A
Data not available
Interest Cover
100.00x
Comfortably covers interest (100.0x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
71.2x
Expensive — P/E 71.2

P/E over 35. The market is pricing in heavy, sustained growth.

P/E vs Forward
+45.3
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (71.2 → 25.9)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial